IP Verse

Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs

Patent No. EP3411402 (titled "Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs") was filed by Amgen on Feb 2, 2017. The application was issued on Dec 22, 2021.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANSep 14, 2022VASILESCU

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3411402

AMGEN
Application Number
EP17703376A
Filing Date
Feb 2, 2017
Status
Granted And Under Opposition
Nov 19, 2021
Publication Date
Dec 22, 2021
External Links
Slate, Register , Google Patents